See more : Rapport Therapeutics, Inc. Common Stock (RAPP) Income Statement Analysis – Financial Results
Complete financial analysis of OptiNose, Inc. (OPTN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OptiNose, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hexima Limited (HXL.AX) Income Statement Analysis – Financial Results
- Public Policy Holding Company, Inc. (PPHC.L) Income Statement Analysis – Financial Results
- Bolt Projects Holdings Inc (BSLKW) Income Statement Analysis – Financial Results
- Mayer Holdings Limited (1116.HK) Income Statement Analysis – Financial Results
- Fortress Value Acquisition Corp. IV (FVIV) Income Statement Analysis – Financial Results
OptiNose, Inc. (OPTN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.optinose.com
About OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.99M | 76.28M | 74.65M | 49.12M | 34.63M | 7.07M | 0.00 | 47.50M | 85.00K |
| Cost of Revenue | 8.63M | 9.26M | 9.15M | 7.52M | 5.29M | 1.59M | 164.00K | 0.00 | 0.00 |
| Gross Profit | 62.35M | 67.01M | 65.50M | 41.60M | 29.34M | 5.48M | -164.00K | 47.50M | 85.00K |
| Gross Profit Ratio | 87.84% | 87.86% | 87.74% | 84.69% | 84.71% | 77.52% | 0.00% | 100.00% | 100.00% |
| Research & Development | 5.30M | 15.26M | 25.32M | 23.38M | 20.78M | 10.10M | 16.83M | 15.31M | 22.16M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 95.62M | 31.70M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 79.80M | 107.65M | 106.63M | 105.44M | 104.16M | 95.62M | 31.70M | 6.87M | 6.01M |
| Other Expenses | 0.00 | -18.94M | -15.85M | -12.57M | -14.45M | -6.42M | -372.00K | 0.00 | 0.00 |
| Operating Expenses | 85.10M | 122.91M | 131.95M | 128.82M | 124.94M | 105.72M | 48.53M | 21.45M | 27.52M |
| Cost & Expenses | 93.74M | 132.17M | 141.10M | 136.34M | 130.23M | 107.31M | 48.53M | 21.45M | 27.52M |
| Interest Income | 2.53M | 513.00K | 52.00K | 426.00K | 2.36M | 2.45M | 303.00K | 143.00K | 28.00K |
| Interest Expense | 19.53M | 16.84M | 15.97M | 13.01M | 9.62M | 9.23M | 910.00K | 3.52M | 819.00K |
| Depreciation & Amortization | 402.00K | 532.00K | 645.00K | 1.45M | 1.11M | 535.00K | 164.00K | 83.00K | 75.00K |
| EBITDA | -15.55M | -57.46M | -65.68M | -85.32M | -99.32M | -96.89M | -48.36M | 25.40M | -27.42M |
| EBITDA Ratio | -21.91% | -73.28% | -89.01% | -177.57% | -276.06% | -1,418.83% | 0.00% | 55.31% | -32,154.12% |
| Operating Income | -22.75M | -55.90M | -66.45M | -87.22M | -95.60M | -100.24M | -48.53M | 25.32M | -28.08M |
| Operating Income Ratio | -32.05% | -73.28% | -89.01% | -177.57% | -276.06% | -1,418.83% | 0.00% | 53.31% | -33,031.76% |
| Total Other Income/Expenses | -12.74M | -18.94M | -15.85M | -12.57M | -14.45M | -6.42M | -372.00K | -2.71M | -237.00K |
| Income Before Tax | -35.48M | -74.83M | -82.30M | -99.79M | -110.05M | -106.66M | -48.90M | 22.61M | -28.31M |
| Income Before Tax Ratio | -49.99% | -98.11% | -110.24% | -203.16% | -317.79% | -1,509.67% | 0.00% | 47.61% | -33,310.59% |
| Income Tax Expense | 0.00 | 1.56M | -646.00K | -1.46M | -1.11M | 2.81M | -164.00K | 3.52M | 819.00K |
| Net Income | -35.48M | -76.40M | -81.65M | -98.33M | -108.95M | -106.66M | -48.90M | 22.61M | -28.31M |
| Net Income Ratio | -49.99% | -100.16% | -109.37% | -200.20% | -314.59% | -1,509.67% | 0.00% | 47.61% | -33,310.59% |
| EPS | -0.32 | -0.89 | -1.44 | -2.04 | -2.60 | -2.68 | -4.45 | 0.36 | -1.06 |
| EPS Diluted | -0.32 | -0.89 | -1.44 | -2.04 | -2.60 | -2.68 | -4.45 | 0.06 | -1.06 |
| Weighted Avg Shares Out | 112.08M | 85.90M | 56.85M | 48.28M | 41.88M | 39.77M | 11.00M | 26.72M | 26.72M |
| Weighted Avg Shares Out (Dil) | 112.08M | 85.90M | 56.85M | 48.28M | 41.88M | 39.77M | 11.00M | 26.72M | 26.72M |
OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2022 Results - Earnings Call Transcript
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
OptiNose: Potential Winner In Chronic Sinusitis Treatment
Best Penny Stocks To Buy Now? 4 To Watch After June's Fed Meeting
Optinose Stock Moves Higher On Positive Second Chronic Sinusitis Phase 3 Trial
OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2022 Results - Earnings Call Transcript
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
Optinose to Present at the Needham Virtual Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports